سعر جينيبرال 0.5 مجم 20 قرص 2022

Gynipral tablets (Arab Drug Company): 20 tablets, each containing hexoprenaline 0.5 mg; a beta-2 sympathomimetic.

• Very common: muscle tremor, tachycardia. Common: hypokalaemia, palpitations, decreased diastolic blood pressure, hypotension, sweating. Uncommon: pulmonary oedema. Rare: hyperglycaemia, cardiac arrhythmias (e.g. atrial fibrillation), myocardial ischaemia, peripheral vasodilatation, nausea. Frequency not known: headache, dizziness, restlessness, vomiting, reduced bowel motility, transient transaminase rise, reduced urine output.General active-ingredient information · BASG Arzneispezialitätenregister (Austrian Federal Office for Safety in Health Care)

• Hypersensitivity to the active substance or excipients; any condition at a gestational age below 22 weeks; pre-existing ischaemic heart disease or significant risk factors for it (as a tocolytic); threatened abortion in the 1st/2nd trimester; any maternal or fetal condition in which prolonging pregnancy is hazardous (e.g. severe toxaemia, intrauterine infection, vaginal bleeding from placenta praevia, eclampsia or severe pre-eclampsia, placental abruption, cord compression); intrauterine fetal death or known lethal congenital/chromosomal malformation.General active-ingredient information · BASG Arzneispezialitätenregister (Austrian Federal Office for Safety in Health Care)
• Heart disease, especially tachyarrhythmias, myocarditis and mitral valve disease; pulmonary hypertension, hypertrophic obstructive cardiomyopathy or any left-ventricular outflow obstruction (e.g. aortic stenosis); hyperthyroidism; severe hepatic or renal disease; angle-closure glaucoma.General active-ingredient information · BASG Arzneispezialitätenregister (Austrian Federal Office for Safety in Health Care)

• Halogenated inhalational anaesthetics (e.g. halothane)Additive hypotensive effect with uterine atony and bleeding risk, and serious ventricular arrhythmias reported; stop treatment at least 6 hours before planned anaesthesia with halogenated anaesthetics where possible.BASG Arzneispezialitätenregister (Austrian Federal Office for Safety in Health Care)
• CorticosteroidsConcomitant use increases the risk of pulmonary oedema, hyperglycaemia and hypokalaemia; close monitoring required.BASG Arzneispezialitätenregister (Austrian Federal Office for Safety in Health Care)
• Antidiabetic medicinesHexoprenaline can raise blood glucose and reduce the effect of antidiabetic treatment.BASG Arzneispezialitätenregister (Austrian Federal Office for Safety in Health Care)
• Potassium-lowering medicines (diuretics, digoxin, methylxanthines, corticosteroids)Increased risk of hypokalaemia and consequent arrhythmias; use with caution after careful benefit-risk assessment.BASG Arzneispezialitätenregister (Austrian Federal Office for Safety in Health Care)
• Non-selective beta-blockersWeaken or abolish the effect of hexoprenaline.BASG Arzneispezialitätenregister (Austrian Federal Office for Safety in Health Care)
• Other sympathomimetics (certain circulatory and asthma medicines)Avoid concomitant use: increased cardiac effects and signs of overdose.BASG Arzneispezialitätenregister (Austrian Federal Office for Safety in Health Care)

• Monitor maternal blood pressure and heart rate, ECG, fluid balance and electrolytes (risk of pulmonary oedema), blood glucose and lactate (especially in diabetics) and serum potassium; monitor fetal heart rate.General active-ingredient information · BASG Arzneispezialitätenregister (Austrian Federal Office for Safety in Health Care)

• Hexoprenaline: Stimulates beta-2 adrenergic receptors, relaxing uterine (and bronchial) smooth muscle.